JP2018516586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516586A5 JP2018516586A5 JP2017564369A JP2017564369A JP2018516586A5 JP 2018516586 A5 JP2018516586 A5 JP 2018516586A5 JP 2017564369 A JP2017564369 A JP 2017564369A JP 2017564369 A JP2017564369 A JP 2017564369A JP 2018516586 A5 JP2018516586 A5 JP 2018516586A5
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- growth factor
- activity
- nanograms
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT20151000047568 | 2015-06-09 | ||
| PT2015047568 | 2015-06-09 | ||
| PT2016032002 | 2016-05-12 | ||
| PT20161000032002 | 2016-05-12 | ||
| PCT/EP2016/063077 WO2016198480A1 (en) | 2015-06-09 | 2016-06-08 | Methods for the production of tcr gamma delta+ t cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516586A JP2018516586A (ja) | 2018-06-28 |
| JP2018516586A5 true JP2018516586A5 (https=) | 2019-07-11 |
| JP6799895B2 JP6799895B2 (ja) | 2020-12-16 |
Family
ID=56132913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564369A Active JP6799895B2 (ja) | 2015-06-09 | 2016-06-08 | ＴＣＲγδ＋Ｔ細胞の生産方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11166983B2 (https=) |
| EP (2) | EP3307875B1 (https=) |
| JP (1) | JP6799895B2 (https=) |
| CN (2) | CN108350428B (https=) |
| AU (3) | AU2016274633B2 (https=) |
| CA (1) | CA2988050A1 (https=) |
| EA (1) | EA201890013A1 (https=) |
| WO (1) | WO2016198480A1 (https=) |
| ZA (1) | ZA201800121B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297773B2 (en) | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| DK3307875T3 (da) | 2015-06-09 | 2022-03-21 | Lymphact Lymphocyte Activation Tech S A | Fremgangsmåder til fremstilling af tcr-gamma-delta+-t-celler |
| WO2017072367A1 (en) * | 2015-10-30 | 2017-05-04 | Cancer Research Technology Limited | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS |
| US11299708B2 (en) | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| JP7002769B2 (ja) * | 2016-09-16 | 2022-02-04 | ベイラー カレッジ オブ メディスン | ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| MX2020005005A (es) | 2017-11-15 | 2020-08-27 | Adicet Bio Inc | Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas. |
| EP3743081A4 (en) * | 2018-01-23 | 2021-12-01 | New York University | SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR |
| GB201804701D0 (en) | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| US20210388100A1 (en) | 2018-10-01 | 2021-12-16 | Adicet Bio, Inc. | Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors |
| SG11202103234RA (en) | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| US12084500B2 (en) | 2019-01-23 | 2024-09-10 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| WO2020172555A1 (en) * | 2019-02-21 | 2020-08-27 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| AU2020290969A1 (en) * | 2019-06-14 | 2022-02-03 | G Tech Bio Llc | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions |
| JP2022545196A (ja) | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗ｔｃｒデルタ可変１抗体の治療的使用 |
| JP7764364B2 (ja) | 2019-08-16 | 2025-11-05 | ガンマデルタ セラピューティクス リミティッド | エクスビボγδ Ｔ細胞集団 |
| CN114555785B (zh) * | 2019-10-17 | 2024-12-06 | 香港大学 | 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法 |
| CN115151565A (zh) | 2019-10-31 | 2022-10-04 | 莫佛塞斯公司 | 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法 |
| GB202002581D0 (en) * | 2020-02-24 | 2020-04-08 | Gammadelta Therapeutics Ltd | Novel antibodies |
| US20210290674A1 (en) * | 2020-03-20 | 2021-09-23 | GammaDelta Therapeutics Ltd. | Methods for treating myeloid malignancies |
| KR20230013022A (ko) | 2020-03-20 | 2023-01-26 | 감마델타 테라퓨틱스 엘티디 | 골수성 악성종양의 치료를 위한 v 델타1+ t 세포 |
| CN113913384A (zh) * | 2020-07-09 | 2022-01-11 | 杭州优凯瑞医药科技有限公司 | 一种制备靶点特异性nk细胞的方法及其应用 |
| PL4269444T3 (pl) | 2020-08-14 | 2025-01-13 | GammaDelta Therapeutics Limited | Wieloswoiste przeciwciała anty-tcr zmienne delta 1 |
| WO2022032665A1 (zh) * | 2020-08-14 | 2022-02-17 | 上海星华生物医药科技有限公司 | 一种制备通用型免疫细胞的方法及其应用 |
| WO2022108627A1 (en) * | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| AU2022224391A1 (en) | 2021-02-17 | 2023-08-24 | Gammadelta Therapeutics Ltd | Anti-tcr delta variable 1 antibodies |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| CA3228168A1 (en) | 2021-08-03 | 2023-02-09 | Gammadelta Therapeutics Ltd | Engineering of gamma delta t cells and compositions thereof |
| KR20240149401A (ko) | 2022-02-16 | 2024-10-14 | 프리오테라 에스에이에스 | S1p 수용체 조정제와 조합된 car 세포를 이용한 치료 방법 |
| GB202204926D0 (en) | 2022-04-04 | 2022-05-18 | Gammadelta Therapeutics Ltd | Method for expanding gammadelta T cells |
| EP4504247A1 (en) | 2022-04-04 | 2025-02-12 | Gammadelta Therapeutics Ltd | Novel gene armoring |
| US11750950B1 (en) * | 2022-05-26 | 2023-09-05 | Omnivision Technologies, Inc. | Voltage domain global shutter readout circuit timing |
| CN115678846B (zh) * | 2022-09-01 | 2023-06-16 | 广东龄值生物科技有限公司 | 一种肿瘤特异性γδT细胞及其制备方法 |
| WO2024193459A1 (en) * | 2023-03-17 | 2024-09-26 | Nanjing Legend Biotech Co., Ltd. | METHODS OF CULTURING Vδ1 T CELLS |
| WO2024209429A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | T cells for use in treating relapsed or refractory acute myeloid leukemia |
| WO2026013616A1 (en) | 2024-07-10 | 2026-01-15 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating cancer |
| WO2026033421A1 (en) | 2024-08-05 | 2026-02-12 | Takeda Pharmaceutical Company Limited | IDENTIFICATION OF SUITABLE DONORS OF γδ T CELLS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE421573T1 (de) * | 1998-11-04 | 2009-02-15 | Therapure Biopharma Inc | Verfahren zur herstellung von gamma delta t zellen |
| US20030157060A1 (en) | 2000-04-03 | 2003-08-21 | Bell David N | Production of tcr gamma delta t cells |
| ES2336302T3 (es) | 2000-04-03 | 2010-04-12 | Therapure Biopharma Inc. | Produccion de celulas ttcr gamma delta. |
| DE602005022728D1 (de) * | 2004-08-19 | 2010-09-16 | Univ Cardiff | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie |
| CN101313061B (zh) * | 2005-11-18 | 2013-05-15 | 大学健康网络 | 扩增双阴性t细胞的方法 |
| US20110158954A1 (en) * | 2007-03-09 | 2011-06-30 | Mitsuko Ideno | Method for producing gamma delta t cell population |
| PL2629605T3 (pl) | 2010-10-21 | 2017-07-31 | Syngenta Limited | Koncentraty agrochemiczne zawierające alkoksylowane adiuwanty |
| PT2710123T (pt) * | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| EP3060059A4 (en) | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| CN113214198B (zh) | 2016-07-18 | 2022-12-23 | 广州瑞安博医药科技有限公司 | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 |
| CN106399245A (zh) * | 2016-11-30 | 2017-02-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种γδT细胞的培养方法 |
-
2016
- 2016-06-08 AU AU2016274633A patent/AU2016274633B2/en active Active
- 2016-06-08 CN CN201680047265.4A patent/CN108350428B/zh active Active
- 2016-06-08 US US15/735,371 patent/US11166983B2/en active Active
- 2016-06-08 CN CN202210397884.3A patent/CN114958738A/zh active Pending
- 2016-06-08 JP JP2017564369A patent/JP6799895B2/ja active Active
- 2016-06-08 CA CA2988050A patent/CA2988050A1/en active Pending
- 2016-06-08 EA EA201890013A patent/EA201890013A1/ru unknown
- 2016-06-08 EP EP16729531.0A patent/EP3307875B1/en active Active
- 2016-06-08 WO PCT/EP2016/063077 patent/WO2016198480A1/en not_active Ceased
- 2016-06-08 EP EP19207256.9A patent/EP3623468A1/en active Pending
-
2018
- 2018-01-08 ZA ZA2018/00121A patent/ZA201800121B/en unknown
-
2022
- 2022-07-15 AU AU2022205271A patent/AU2022205271A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/955,830 patent/US20250152630A1/en active Pending
-
2025
- 2025-04-23 AU AU2025202866A patent/AU2025202866A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516586A5 (https=) | ||
| Karachi et al. | Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition | |
| Kratchmarov et al. | TCF1 expression marks self-renewing human CD8+ T cells | |
| Li et al. | Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma | |
| Meng et al. | Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application | |
| Icheva et al. | Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation | |
| Muliaditan et al. | Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer | |
| Fridlender et al. | Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms | |
| Orange et al. | Coley’s lessons remembered: augmenting mistletoe therapy | |
| Marçais et al. | The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells | |
| Wang et al. | Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma | |
| Draghiciu et al. | Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination | |
| Sköld et al. | Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells | |
| Weir et al. | Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response | |
| EP4034639A1 (en) | Compositions comprising regulatory t cells and methods of making and using the same | |
| CN109439627B (zh) | 一种极化和扩增cd4+t细胞的方法及组合物及在治愈表达特异性抗原的肿瘤中的应用 | |
| CN117377755A (zh) | 包含调节性t细胞的组合物及其使用方法 | |
| Liu et al. | IL-2/GM-CSF enhances CXCR3 expression in car-T cells via the PI3K/akt and ERK1/2 pathways | |
| Li et al. | Dendritic cells therapy with cytokine-induced killer cells and activated cytotoxic T cells attenuated Th2 bias immune response | |
| Song et al. | Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma | |
| Da Silva et al. | Immunostimulatory activity of the cytokine-based biologic, IRX-2, on human papillomavirus-exposed Langerhans cells | |
| Liu et al. | Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity | |
| CA2405050A1 (en) | Production of tcr gamma delta t cells | |
| Gong et al. | Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis | |
| CN102212505B (zh) | 免疫杀手细胞及其制造方法,包含其的医药组成物及套组 |